BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.93B |
| 2 |
Amazon
AMZN
|
+$430M |
| 3 |
Microsoft
MSFT
|
+$344M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$323M |
| 5 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$345M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$305M |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$305M |
| 4 |
PPLI
People Inc
PPLI
|
+$203M |
| 5 |
Visa
V
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12% |
| 2 | Consumer Discretionary | 7.3% |
| 3 | Healthcare | 5.39% |
| 4 | Financials | 5.24% |
| 5 | Communication Services | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TUFN
2776
DELISTED
Tufin Software Technologies Ltd.
TUFN
| $143K | ﹤0.01% |
17,378
+4,619
| +36% | +$44.9K |
|
2777
Virtu Financial
VIRT
$5.04B
| $143K | ﹤0.01% |
6,225
-82,755
| -93% | -$2.08M |
|
2778
Monarch Casino & Resort
MCRI
$2.22B
| $143K | ﹤0.01% |
3,211
+2,470
| +333% | +$101K |
|
|
KRA
2779
DELISTED
Kraton Corporation
KRA
| $143K | ﹤0.01% |
8,034
+5,284
| +192% | +$85.1K |
|
|
PRVB
2780
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $143K | ﹤0.01% |
11,155
+9,544
| +592% | +$121K |
|
|
DCOM
2781
DELISTED
Dime Community Bancshares
DCOM
| $143K | ﹤0.01% |
12,649
+10,282
| +434% | +$128K |
|
2782
ATN International
ATNI
$478M
| $143K | ﹤0.01% |
2,849
+1,896
| +199% | +$108K |
|
2783
Armstrong World Industries
AWI
$7.75B
| $143K | ﹤0.01% |
2,075
-8,096
| -80% | -$592K |
|
2784
Veeco
VECO
$3.26B
| $143K | ﹤0.01% |
12,211
+8,301
| +212% | +$106K |
|
2785
MGP Ingredients
MGPI
$381M
| $142K | ﹤0.01% |
3,565
+2,513
| +239% | +$93.7K |
|
2786
BioCryst Pharmaceuticals
BCRX
$2.51B
| $142K | ﹤0.01% |
41,204
+5,467
| +15% | +$23.4K |
|
|
VAPO
2787
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $141K | ﹤0.01% |
608
+513
| +540% | +$148K |
|
|
MDP
2788
DELISTED
Meredith Corporation
MDP
| $141K | ﹤0.01% |
10,737
+5,962
| +125% | +$83.3K |
|
|
TBI
2789
Trueblue
TBI
$302M
| $141K | ﹤0.01% |
9,092
+5,726
| +170% | +$88.3K |
|
2790
Omeros
OMER
$1.26B
| $141K | ﹤0.01% |
13,931
+11,809
| +557% | +$152K |
|
2791
OrthoPediatrics
KIDS
$653M
| $141K | ﹤0.01% |
3,064
+2,617
| +585% | +$121K |
|
2792
Rio Tinto
RIO
$160B
| $140K | ﹤0.01% |
2,323
-8,016
| -78% | -$492K |
|
|
CKH
2793
DELISTED
Seacor Holdings Inc.
CKH
| $140K | ﹤0.01% |
4,823
+3,342
| +226% | +$99.2K |
|
|
KNL
2794
DELISTED
Knoll, Inc.
KNL
| $140K | ﹤0.01% |
11,628
-57,697
| -83% | -$713K |
|
2795
PDF Solutions
PDFS
$2.19B
| $140K | ﹤0.01% |
7,494
+5,833
| +351% | +$120K |
|
2796
World Acceptance Corp
WRLD
$875M
| $140K | ﹤0.01% |
1,327
+846
| +176% | +$70.3K |
|
2797
Arlo Technologies
ARLO
$1.5B
| $140K | ﹤0.01% |
26,602
+15,146
| +132% | +$72.8K |
|
2798
Protagonist Therapeutics
PTGX
$9.8B
| $139K | ﹤0.01% |
7,106
+6,250
| +730% | +$117K |
|
2799
Krystal Biotech
KRYS
$9.72B
| $139K | ﹤0.01% |
3,223
+1,675
| +108% | +$72.7K |
|
|
DBD
2800
DELISTED
Diebold Nixdorf Incorporated
DBD
| $138K | ﹤0.01% |
18,078
+12,840
| +245% | +$94.4K |
|
Similar funds
BNP Paribas Financial Markets's Q3 2020 Portfolio in Review
As of Q3 2020, BNP Paribas Financial Markets held 4,385 positions worth $69.9B, up 23% from $56.7B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
BNP Paribas Financial Markets deployed $2.99B of net new capital in Q3 2020, opening 85 new positions and adding to 2,667 existing holdings. Its largest new stake was iShares MSCI USA Value Factor ETF: 270,001 shares worth $19.9M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 13% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was State Street SPDR S&P Biotech ETF, an estimated $345M trimmed.
- BNP Paribas Financial Markets's largest Q3 2020 buy was iShares MSCI USA Value Factor ETF: 270,001 shares worth $19.9M.
- BNP Paribas Financial Markets added most to Invesco QQQ Trust in Q3 2020, an estimated $1.93B increase.
- BNP Paribas Financial Markets's biggest Q3 2020 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $345M.
- BNP Paribas Financial Markets fully exited People Inc in Q3 2020, selling an estimated $203M.
- BNP Paribas Financial Markets's ten largest holdings make up 22% of its $69.9B portfolio in Q3 2020.
- BNP Paribas Financial Markets opened 85 new positions and closed 175 in Q3 2020.
- BNP Paribas Financial Markets's portfolio value rose 23% quarter-over-quarter to $69.9B.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2020, filed 30 Oct 2020.